The California pharma has elected to move forward with all three autoimmune programs in its $240 million pact with EVOQ Therapeutics, the companies said Wednesday. EVOQ received an undisclosed milestone payment.
ANN ARBOR, Mich., Jan. 9, 2023 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases, today announced the appointment of David Giljohann, Ph.D., as Chief Executive Officer. Dr. Giljohann will also serve as a member of the Board. The company also announced the appointment of Greg Barrett as Chief Operating Officer.